Clinical Study On The Curative Effect And Safty Of Fuzhi Capsule In Treatment With Vascular Dementia

Objective: Observed Fuzhi Capsule on vascular dementia (Vascular Dementia, VD) clinical efficacy; by monitoring the medication before and after the blood rheology, NO content of relevant indicators such as changes in observation Fuzhi capsule on related indicators, the incidence of VD.Methods:Randomized clinical study design by simply using the DSM-IV (the United States, "Psychiatric Diagnostic and Statistical Manual") and the NINDS-AIREN (National Institute of Nervous System Disorders and Stroke Neuroscience Research Institute and the International Association of Switzerland) on the diagnostic criteria of VD for case selection, And with the Montreal Assessment Scale (MOCA), capacity assessment scale (BBS), and Jinzhou, etc., "the purpose of clinical trials in vascular dementia Syndrome Scale" (SDSVD) for the kidney essence deficiency syndrome, phlegm blocking orifices based TCM Standard on the overall assessment of patients. The patient agreed to meet the standards will be included in study, 60 patients were randomly divided into treatment group and control group 30 cases; treatment group was treated with 4 tablets per Fuzhi capsule 3 times a day; the control group was treated with Aricept , a / time, 1 times / day. Both groups of atorvastatin 12 weeks. Before treatment, l2 weeks after treatment the patients MOCA, BBS and TCM assessment indicators. Rheology observed before and after treatment, NO levels and other related indices. Safety observations with blood, urine, stool, ECG, liver function, kidney function, blood lipids, blood sugar, head CT, etc., respectively examination before treatment and after treatment.Results:60 patients completed clinical trials by the program, no cases of detached and removed. Treatment group and control group after treatment MOCA score in a = 0.05 level within the group there was significant difference (P<0.05), between the two groups no significant difference (P>0.05); Two BBS score, the symptom score and individual symptoms and signs at a = 0.05 level on the group and between groups were statistically significant differences in the treatment group than the control group(P<0.05). Determine clinical efficacy in the treatment group MOCA total effective rate was 70.0%, 76.7% in the control group, the difference at a = 0.05 level was not statistically significant; treatment group BBS and the symptom score and so the total effective rate was 83.3%, 80.0%, while the control group were 80.0%, 73.3%, the difference in the a = 0.05 level by a significant difference (between the two groups: BBS, P<0.05; TCM syndrome score, P <0.05); two groups of patients Chinese medicine treatment of individual symptoms before and after theα= 0.05 level within the group and between groups were statistically significant (P<0.05); medication before and after both whole blood viscosity and plasma viscosity, hematocrit, serum NO levels in a = 0.05 compared with the standard of the group significant difference (P<0.05), between the two groups no significant difference (P>0.05).Conclusion: Complex Chi capsule and Aricept may improve cognitive function in patients with VD, in improving non-cognitive function (life skills, daily habits and personality changes, etc.) and TCM syndrome, especially in improving the intelligence decline, weak waist brain transfer tinnitus, good surprise, and two will be easy to fear from the left and so individual clinical symptoms, the complex is better than Aricept Chi capsule. Indicators for monitoring that Fuzhi capsule exactly the whole blood viscosity and plasma viscosity, red blood cell characteristics, lower levels of serum NO.